[Immunomodulating properties of leukinferon].
Tolerance and immunomodulating properties of leukinferon for injections were studied in 13 healthy volunteers. The drug was administered by inhalation and intramuscularly in a single dose of 10,000 MU twice daily for 3 days. Intramuscular injections of the drug were accompanied by a number of side effects: pyrogenicity, weakness, headache, that ceased 8-12 hrs after the drug was discontinued. Despite these side effects, the drug was satisfactorily tolerated. Neither viscera nor systemic disorders nor allergic reactions were detected. T-lymphocytes proved to be the most sensitive to the drug. Leukinferon was found to activate the interferon system. The effect was the most marked in respect of IRL-gamma.
Iushchuk
N D
ND
Zmyzgova
A V
AV
Tugutova
I V
IV
Kuznetsov
V P
VP
Babaiants
A A
AA
Novikova
T A
TA
Eremina
O F
OF
Mesniankin
A P
AP
Lebedev
V V
VV
V'iushina
M A
MA
D000276:Adjuvants, Immunologic; D000280:Administration, Inhalation; D000328:Adult; D016207:Cytokines / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects* / Q000276:immunology; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C062252:leukinferon
Immunomoduliruiushchie svoĭstva leĭkinferona.